# Evaluating the Efficacy and Safety of Roflumilast in Patients with NASH

> **NCT06677788** · PHASE2 · COMPLETED · sponsor: **Tanta University** · enrollment: 55 (actual)

## Conditions studied

- Non-Alcoholic Steatohepatitis (NASH)

## Interventions

- **DRUG:** Roflumilast 500 Mcg Oral Tablet
- **DRUG:** Vitamin E capsule

## Key facts

- **NCT ID:** NCT06677788
- **Lead sponsor:** Tanta University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-01
- **Primary completion:** 2024-09-20
- **Final completion:** 2024-10-15
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2024-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06677788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06677788, "Evaluating the Efficacy and Safety of Roflumilast in Patients with NASH". Retrieved via AI Analytics 2026-08-21 from https://api.ai-analytics.org/clinical/NCT06677788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*